Cargando…

Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey

INTRODUCTION: Talimogene laherparepvec is a first-in-class oncolytic immunotherapy for intratumoral injection with proven efficacy and tolerability in patients with unresectable early metastatic melanoma (stage IIIB–IVM1a) in the pivotal phase III OPTiM study. The objective was to characterize melan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohr, Peter, Haferkamp, Sebastian, Pinter, Andreas, Weishaupt, Carsten, Huber, Margit A., Downey, Gerald, Öhrling, Katarina, Loquai, Carmen, Louie, Karly S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318239/ https://www.ncbi.nlm.nih.gov/pubmed/30536143 http://dx.doi.org/10.1007/s12325-018-0850-6

Ejemplares similares

A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries
por: van Akkooi, Alexander C. J., et al.
Publicado: (2020)

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
por: Harrington, Kevin J, et al.
Publicado: (2016)

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
por: Malvehy, Josep, et al.
Publicado: (2021)

Talimogene laherparepvec: First in class oncolytic virotherapy
por: Conry, Robert M., et al.
Publicado: (2018)

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec
por: McClure, Erin M., et al.
Publicado: (2022)

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec
por: Blackmon, Jonathan T., et al.
Publicado: (2017)

A practical guide to the handling and administration of talimogene laherparepvec in Europe
por: Harrington, Kevin J, et al.
Publicado: (2017)

Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
por: Dummer, Reinhard, et al.
Publicado: (2017)

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
por: Kaufman, Howard L., et al.
Publicado: (2022)

Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
por: Orloff, Marlana
Publicado: (2016)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
por: Andtbacka, Robert H.I., et al.
Publicado: (2019)

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection
por: Shmuylovich, Leonid, et al.
Publicado: (2022)

Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
por: Park, Song Y, et al.
Publicado: (2022)

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy
por: Zhang, Tiantian, et al.
Publicado: (2023)

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma
por: Swami, Umang, et al.
Publicado: (2019)

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC)
por: Mulder, Evalyn E. A. P., et al.
Publicado: (2021)

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec
por: Lebhar, Jamie, et al.
Publicado: (2023)

Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients
por: Fröhlich, Anne, et al.
Publicado: (2020)

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
por: Rehman, Hasan, et al.
Publicado: (2016)

Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy
por: Rizzo, Jason M., et al.
Publicado: (2018)

Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases
por: Blackmon, Jonathan T., et al.
Publicado: (2017)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
por: Long, Georgina V, et al.
Publicado: (2015)

Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
por: Quinn, Casey, et al.
Publicado: (2016)

Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)
por: Perez, Matthew C, et al.
Publicado: (2019)

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
por: Ressler, Julia Maria, et al.
Publicado: (2021)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
por: Tijtgat, Jens, et al.
Publicado: (2021)

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
por: Kai, Megumi, et al.
Publicado: (2021)

A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2022)

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec
por: Singh, Neha, et al.
Publicado: (2023)

Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient
por: Miller, Max, et al.
Publicado: (2023)

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
por: Chesney, Jason A., et al.
Publicado: (2023)

Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial
por: Kaufman, Howard L, et al.
Publicado: (2014)

Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)
por: Sun, James, et al.
Publicado: (2020)

Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients
por: Westbrook, Brian C., et al.
Publicado: (2019)

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Publicado: (2021)

Talimogene laherparepvec resulting in near‐complete response in a patient with treatment‐refractory Merkel cell carcinoma
por: Cilento, Michael A., et al.
Publicado: (2022)

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma
por: Beekman, Kate E., et al.
Publicado: (2023)

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
por: Andtbacka, Robert H. I., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o9s85iahab0hqmnf9le2siidns